The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Alliance News Detail


3Legs To Change Name To SalvaRx After Agreeing Reverse Takeover (ALLISS)

[ 03 Mar 2016 09:51 ]

LONDON (Alliance News) - 3Legs Resources PLC on Thursday said it has agreed a reverse takeover SalvaRx Ltd and said it will raise funds in a share placing for working capital requirements.

3Legs will change its name to SalvaRx Group PLC following completion of the deal.

3Legs said it will acquire the rest of SalvaRx Ltd it does not already own for GBP8.8 million, to be satisfied by the issue of 24.8 million shares at 35.5 pence per share and constituting a reverse takeover. The stock is suspended from trading on AIM, last quoted at 0.288p.

SalvaRx is a cancer immunotherapy development company and owns a 61% stake in iOx, a compkany developing a series of cancer immunotherapy compounds.

"We are very pleased to have agreed the acquisition of SalvaRx, subject to shareholder approval. The business has a strong and experienced management team in the cancer immunotherapy sector which is an exciting and fast growing market," said Richard Armstrong.

In addition, 3Legs said it will raise around GBP2.0 million through a placing of shares at the same 35.5p to provide working capital for the enlarged group, implying it will issue around 5.6 million shares.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.


3Legs To Change Name To SalvaRx After Agreeing Reverse Takeover (ALLISS) - Alliance News

The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds